Based on the findings of the AURA series studies [2, 3, 4], osimertinib is also the standard care in NSCLC harboring EGFR T790M mutation after disease progression on the treatment of first‐ or second‐generation EGFR‐TKI. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.